Stefanie Maurer

Stefanie Maurer is a Senior Scientist at Indapta Therapeutics since November 2024, focusing on allogeneic FcRγ-deficient natural killer cell therapy for cancer treatment. Previously, Stefanie held the role of Senior Scientist at ImmuneBridge, specializing in cellular screening and efficacy studies from April 2023 to November 2024. Stefanie's research experience includes a postdoctoral role at the Precision Immunology Institute at Icahn School of Medicine at Mount Sinai, where novel immunotherapeutic approaches to enhance Natural Killer cell activity were explored. Additionally, Stefanie has contributed to cancer immunotherapy and molecular imaging as a Research Scholar at Memorial Sloan Kettering Cancer Center and served as a Junior Research Group Leader at CCU Translational Immunology DKTK/DKFZ in Germany. Educational credentials include a PhD in Biochemistry from the German Cancer Research Center and the Hospital of the University of Tübingen, along with a Diploma in Biochemistry from the University of Tübingen. Prior academic experience includes research internships at the Max Planck Institute for Biochemistry and the Max Planck Institute for Developmental Biology.